Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12660498 | 0.93 | MEN1 (0.53) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL276131 | 0.82 | MEN1 (0.39) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL13612087 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL12660513 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL18227261 | 0.79 | KDM4E (0.56) | ALDH1A1SMN1; SMN2TSHRKDM4EMAPK1 | |
| SCHEMBL17398955 | 0.77 | MEN1 (0.34) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL14287509 | 0.77 | MEN1 (0.34) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL15713279 | 0.77 | NAAA (0.46) | ALDH1A1TSHRMEN1KMT2AFAAH | |
| SCHEMBL18227240 | 0.75 | KMT2A (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5830059 | 0.75 | ALDH1A1 (0.83) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877829-B2 | Process for making cationic hydrophilic siloxanyl monomers | BAUSCH & LOMB INCORPORATED (US) | 2014-11-04 | — | — | US | disclosed |
| US-8133512-B2 | Drug delivery systems based on catonic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133511-B2 | Drug delivery system based on cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2012-03-13 | — | — | US | disclosed |
| US-7960447-B2 | Cationic end-capped siloxane prepolymer for reduced cross-link density | BAUSCH & LOMB INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-7934830-B2 | High water content silicone hydrogels | BAUSCH & LOMB INCORPORATED (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110015298-A1 | PROCESS FOR MAKING CATIONIC HYDROPHILIC SILOXANYL MONOMERS | SANTARUS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-7759408-B2 | Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups | BAUSCH & LOMB INCORPORATED (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090274745-A1 | Drug delivery systems based on catonic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274744-A1 | Drug delivery system based on cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-7579021-B2 | Drug delivery systems based on degradable cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080152540-A1 | PACKAGING SOLUTIONS | BAUSCH & LOMB INCORPORATED (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080075780-A1 | Drug delivery systems based on degradible cationic siloxanyl macromonomers | SANTARUS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070242215-A1 | Cationic end-capped siloxane prepolymer for reduced cross-link density | BAUSCH & LOMB INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070149428-A1 | Method of Packaging a Lens | BAUSCH & LOMB INCORPORATED (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070142584-A1 | Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups | LABORATOIRE CHAUVIN S.A.S. (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070242215-A1 | Cationic end-capped siloxane prepolymer for reduced cross-link density | VCL, SDC1, SDC2 | ALDH1A1 4609/4885SMN1; SMN2 3482/4885TSHR 4384/4885 |
| US-20080152540-A1 | PACKAGING SOLUTIONS | AQP1, ARGLU1, CRYZ | ALDH1A1 4081/4885SMN1; SMN2 3337/4885TSHR 3664/4885 |
| US-20070142584-A1 | Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups | STIM1, ORAI1, ORAI3 | ALDH1A1 4396/4885SMN1; SMN2 1546/4885TSHR 4492/4885 |
| US-20090274744-A1 | Drug delivery system based on cationic siloxanyl macromonomers | MSR1, LPXN, SRRM2 | ALDH1A1 3479/4885SMN1; SMN2 609/4885TSHR 2302/4885 |
| US-20090274745-A1 | Drug delivery systems based on catonic siloxanyl macromonomers | MMP13, LPXN, SLC13A2 | ALDH1A1 1770/4885SMN1; SMN2 839/4885TSHR 2498/4885 |
| US-20110015298-A1 | PROCESS FOR MAKING CATIONIC HYDROPHILIC SILOXANYL MONOMERS | ILK, SAMM50, AAAS | ALDH1A1 2442/4885SMN1; SMN2 4341/4885TSHR 4765/4885 |
| US-20080075780-A1 | Drug delivery systems based on degradible cationic siloxanyl macromonomers | MSR1, LPXN, SRRM2 | ALDH1A1 3230/4885SMN1; SMN2 877/4885TSHR 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.